This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
8718 GLP-1RA-associated tumors were reported, with significant signals for thyroid and pancreatic cancers.
Why it matters
Understanding the potential risks associated with GLP-1RAs is crucial for patient safety, especially given their widespread use in diabetes management. This research provides valuable insights for clinicians regarding the monitoring of tumor-related adverse effects.
How the study worked
The study utilized disproportionality analysis on FAERS data from 2004 to 2021 to assess the relationship between GLP-1RAs and tumor occurrences.
What this study cannot tell us
The study relies on reported data, which may be subject to underreporting or misclassification of cases.
Read the original research
GLP-1 receptor agonist-associated tumor adverse events: A real-world study from 2004 to 2021 based on FAERS.
Frontiers in pharmacology, 13, 925377
Citation
Yang, Zheng; Lv, Yuhuan; Yu, Meng; Mei, Mei; Xiang, Linyu; Zhao, Subei; Li, Rong. (2022). GLP-1 receptor agonist-associated tumor adverse events: A real-world study from 2004 to 2021 based on FAERS.. Frontiers in pharmacology, 13, 925377. https://doi.org/10.3389/fphar.2022.925377